… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … “The visual field improvements observed indicate that RNAtherapy could potentially be used to treat early stage …
Top-line data from Phase 2/3 pivotal Illuminate trial of sepofarsen for CEP290-mediated LCA10 on track for H1 2022
QR-421a pivotal Sirius and Celeste Phase 2/3 trials in Usher syndrome and retinitis pigmentosa expected to start by yea
… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced the … Sirius and Celeste clinical trials of investigational RNAtherapy QR-421a for people with USH2A mediated retinitis …
… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today reported its … Sepofarsen Sepofarsen (QR-110) is an investigational RNAtherapy designed to restore vision in Leber congenital …
Top-line data from pivotal Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated LCA10 anticipated late Q1/early Q2 2022
Five-target collaboration with Lilly highlights significant potential of ProQR’s Axiomer® RNA base-editing pla
Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022
Positive data reported from the Phase 1/2 clinical trial of QR-421a for the treatment of Usher syndrome and non-syndromic retini
… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … Phase 1b/2 trial results of intravitreal sepofarsen RNAtherapy in Leber congenital amaurosis 10 (LCA10) Presenter: …
… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … Phase 1b/2 trial results of intravitreal sepofarsen RNAtherapy in Leber congenital amaurosis 10 (LCA10) Presenter: …
… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … amaurosis 10 (LCA10) and the investigational RNAtherapy for LCA10, sepofarsen experience to date. The call …